Strategies for vaccine delivery

Journal of Drug Targeting

Volumn 11, Issue 8-10, 2003, Pages 459-461

  Oya Alpar, H ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL DNA; BACTERIAL VACCINE; BCG VACCINE; COMPLEMENT RECEPTOR; DNA VACCINE; DRUG CARRIER; MANNOSE RECEPTOR; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; PERTUSSIS VACCINE; SMALLPOX VACCINE; TOLL LIKE RECEPTOR; VACCINE;

ALLERGY; BACTERIAL INFECTION; CPG ISLAND; DRUG DELIVERY SYSTEM; DRUG SAFETY; DRUG TARGETING; EDITORIAL; FEBRILE CONVULSION; HUMAN; HYPERCHOLESTEROLEMIA; IMMUNE SYSTEM; MUSCLE HYPOTONIA; NONHUMAN; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SMALLPOX; YERSINIA PESTIS; YERSINIOSIS;

ADJUVANTS, IMMUNOLOGIC; HUMANS; IMMUNITY, NATURAL; VACCINES; VACCINES, ATTENUATED; VACCINES, SYNTHETIC;

EID: 1942443164     PISSN: 1061186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/10611860410001683013     Document Type: Editorial

References (27)

1. Almeida, A.J. and Alpar, H.O. (1996) "Nasal delivery of vaccines", J. Drug Target. 3, 455-467.
2. Alpar, H.O. and Almeida, A.J. (1994) "Identification of some of the physico-chemical characteristics of microspheres which influence the induction of thr immune response following mucosal delivery", Eur. J. Pharm. Biopharm. 40, 198-202.
3. Alpar, H.O. and Bramwell, V.W. (2002) "Current status of DNA vaccines and their route of administration", Crit. Rev. Ther. Drug Carrier Syst. 19, 307-383.
4. Alpar, H.O., Bowen, J.C. and Brown, M.R.W. (1992) "Effectiveness of liposomes as adjuvants of orally and nasally administered tetanus toxoid", Int. J. Pharm. 88, 335-344.
5. Alpar, H.O., Almeida, A.J. and Brown, M.R. (1994) "Microsphere absorption by the nasal mucosa of the rat", J. Drug Target. 2, 147-149.
6. Alpar, H.O., Ozsoy, Y., Bowen, J.C., Eyles, J., Conway, B.R. and Williamson, D.E. (1996) "Potential of particulate carriers for the mucosal delivery of DNA vaccines", Immunology 89, CC337-CC337.
7. Alpar, H.O., Eyles, J.E., Williamson, E.D. and Somavarapu, S. (2001) "Intranasal vaccination against plague, tetanus and diphtheria", Adv. Drug Deliv. Rev. 51, 173-201.
8. Capiau, C., Poolman, J., Hoet, B., Bogaerts, H. and Andre, F. (2003) "Development and clinical testing of multivalent vaccines based on a diphtheria-tetanus-acellular pertussis vaccine: difficulties encountered and lessons learned", Vaccine 21, 2273-2287.
9. Degen, W.G., Jansen, T. and Schijns, V.E. (2003) "Vaccine adjuvant technology: from mechanistic concepts to practical applications", Expert Rev. Vaccines 2, 327-335.
10. Eyles, J., Alpar, O., Field, W.N., Lewis, D.A. and Keswick, M. (1995) "The transfer of polystyrene microspheres from the gastrointestinal tract to the circulation after oral administration in the rat", J. Pharm. Pharmacol. 47, 561-565.
11. Eyles, J.E., Alpar, H.O., Conway, B.R. and Keswick, M. (1997) "Oral delivery and fate of poly(lactic acid) microsphere-encapsulated interferon in rats", J. Pharm. Pharmacol. 49, 669-674.
12. Eyles, J.E., Sharp, G.J.E., Williamson, E.D., Spiers, I.D. and Alpar, H.O. (1998) "Intra nasal administration of poly-lactic acid microsphere co- encapsulated Yersinia pestis subunits confers protection from pneumonic plague in the mouse", Vaccine 16, 698-707.
13. Eyles, J.E., Williamson, E.D. and Alpar, H.O. (2000) "Intranasal administration of influenza vaccines - current status", Biodrugs 13, 35-59.
14. Eyles, J.E., Bramwell, V.W., Williamson, E.D. and Alpar, H.O. (2001) "Microsphere translocation and immunopotentiation in systemic tissues following intranasal administration", Vaccine 19, 4732-4742.
15. Fujihashi, K., Dohi, T., Rennert, P.D., Yamamoto, M., Koga, T., Kiyono, H. and McGhee, J.R. (2001) "Peyer's patches are required for oral tolerance to proteins", PNAS 98, 3310-3315.
16. Janeway, C.A., Jr. (1992) "The immune system evolved to discriminate infectious nonself from noninfectious self", Immunol. Today 13, 11-16.
17. Klinman, D.M., Barnhart, K.M. and Conover, J. (1999) "CpG motifs as immune adjuvants", Vaccine 17, 19-25.
18. Lasic, D.D. and Templeton, N.S. (1996) "Liposomes in gene therapy", Adv. Drug Deliv. Rev. 20, 221-266.
19. Le Saux, N., Barrowman, N.J., Moore, D.L., Whiting, S., Scheifele, D. and Halperin, S. (2003) "Decrease in hospital admissions for febrile seizures and reports of hypotonic-hyporesponsive episodes presenting to hospital emergency departments since switching to acellular pertussis vaccine in Canada: a report from IMPACT", Pediatrics 112, e348.
20. Li, X.W., Lee, D.K., Chan, A.S. and Alpar, H.O. (2003) "Sustained expression in mammalian cells with DNA complexed with chitosan nanoparticles", Biochim. Biophys. Acta 1630, 7-18.
21. Liu, M.A. (1999) "Vaccines timeline. Interview by Philip Cohen", BMJ 319, 1301.
22. van der Lubben, I.M., van Opdorp, F.A., Hengeveld, M.R., Onderwater, J.J., Koerten, H.K., Verhoef, J.C., Borchard, G. and Junginger, H.E. (2002) "Transport of chitosan microparticles for mucosal vaccine delivery in a human intestinal M-cell model", J. Drug Target. 10, 449-456.
23. McCluskie, M.J., Chu, Y., Xia, J.L., Jessee, J., Gebyehu, G. and Davis, H.L. (1998) "Direct gene transfer to the respiratory tract of mice with pure plasmid and lipid-formulated DNA", Antisense Nucleic Acid Drug Dev. 8, 401-414.
24. Ogra, P.L., Chiba, Y., Beutner, K.R. and Morag, A. (1976) "Vaccination by non-parenteral routes: characteristics of immune response", Dev. Biol. Stand. 33, 19-26.
25. Perrie, Y., Frederik, P.M. and Gregoriadis, G. (2001) "Liposome-mediated DNA vaccination: the effect of vesicle composition", Vaccine 19, 3301-3310.
26. Schijns, V.E. (2003) "Mechanisms of vaccine adjuvant activity: initiation and regulation of immune responses by vaccine adjuvants", Vaccine 21, 829-831.
27. Ying, H., Zaks, T.Z., Wang, R.F., Irvine, K.R., Kammula, U.S., Marincola, F.M., Leitner, W.W. and Restifo, N.P. (1999) " Cancer therapy using a self-replicating RNA vaccine", Nat. Med. 5, 823-827.